Our findings suggest that targeting SDF-1 and TGFβ in BM using a triple-combination with BTZ, LEN, and Thal, potentially improve the response of myeloma cells by increasing the inhibition of myeloma cell growth and activating the endogenous immune surveillance against tumor antigens. Here, CXCL12 is linked to plasma cell myeloma.